Industry-Led Consortium Developing a Novel Paradigm for Cardiac Safety Evaluation of New Drugs SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/22/14 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue and regenerative

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/23/14 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue and regenerative medicine, today announced that the United States Patent and Trademark Office has issued a Notice of

Collaboration Focused on Improving Cardiac Safety of Medical Products Based Upon Principles of FDA's Critical Path Initiative SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/10/14 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/28/13 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announced an update on the status of its strategic financing

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/17/13 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, presented key developments involving its  CardioSafe  3D™ and  LiverSafe  3D™

Living Heart Muscle Derived From Human Stem Cells Is Closest Man-Made Approximation of Natural Human Heart Muscle to Date SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/07/13 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue,

Proceeds Will Accelerate Stem Cell Technology-Based Drug Rescue, Predictive Toxicology and Drug Metabolism Programs SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/10/13 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive

Proceeds Will Accelerate Stem Cell Technology-Based Drug Rescue, Predictive Toxicology and Drug Metabolism Programs SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/10/13 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/12/13 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announces that it will present key enhancements to LiverSafe 3D™, its

Poster Will Discuss Expanded and Improved Applications of Novel Pluripotent Stem-Based Screening System for Heart Toxicity SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/11/13 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue,